Micofenolato De Mofetilo Aristo

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetilo Aristo, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis in appropriate patients.

GNH USA supplies Micofenolato De Mofetilo Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in several immunologically mediated conditions, primarily to reduce graft rejection and renal inflammation.

Kidney transplant rejection: helps prevent organ rejection in kidney transplant recipients. Heart transplant rejection: helps prevent organ rejection in heart transplant recipients. Liver transplant rejection: helps prevent organ rejection in liver transplant recipients. Lupus nephritis: reduces kidney inflammation in patients with systemic lupus erythematosus.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: transient head pain. - Infections: increased susceptibility to bacterial, viral or fungal infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count. - Severe infections: opportunistic or life‑threatening infections. - Malignancy: increased risk of certain cancers. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy: rare demyelinating brain disease.

Patients receiving Mycophenolate Mofetil should be monitored closely for safety concerns.

Monitor blood counts: perform regular CBC to detect leukopenia or anemia. Assess renal function: adjust dose in renal impairment and monitor creatinine. Avoid live vaccines: immunosuppression can render live vaccines unsafe. Pregnancy: drug is category D; avoid unless benefits outweigh risks. Store at below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine: increased mycophenolate exposure, raising toxicity risk. - Rituximab: heightened infection risk when combined.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption of mycophenolic acid. - Live‑attenuated vaccines: monitor immune response and infection risk. - Warfarin: possible effect on INR; require more frequent coagulation monitoring.